3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Tertiary Lymphoid Structures
1
Sarcoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Interventions
Cyclophosphamide
423
Trastuzumab
414
Paclitaxel
375
Docetaxel
314
Capecitabine
266
Letrozole
262
Carboplatin
257
Doxorubicin
213
Tamoxifen
184
Fulvestrant
176
Epirubicin
176
Radiotherapy
171
Anastrozole
164
pembrolizumab
152
pertuzumab
147
Surveys and Questionnaires
146
Exercise
142
exemestane
128
Vinorelbine
127
palbociclib
124
Bevacizumab
123
Magnetic Resonance Spectroscopy
120
Blood Specimen Collection
120
Drug Therapy
106
Albumin-Bound Paclitaxel
105
Gemcitabine
99
130-nm albumin-bound paclitaxel
98
pyrotinib
92
eribulin
90
Biopsy
88
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
brigimadlin
×
Breast
×
Clear all
NCT06084689
2025-09-02
EMPIRE
Institut Bergonié
Phase 2
Withdrawn